Current perspectives in the treatment of resistant schizophrenia

Indian Journal of Psychiatry

Volumn 51, Issue 4, 2009, Pages 254-260

  Solanki, R K ^a   Singh, Paramjeet ^a   Munshi, Deepti ^a  

^a SMS MEDICAL COLLEGE   (India)

Author keywords

Adjuvant therapy; Clozapine; Treatment resistance

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; GALANTAMINE; GLYCINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PIMOZIDE; PLACEBO; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; ELECTROCONVULSIVE THERAPY; GOLD STANDARD; HUMAN; MANIA; MOOD DISORDER; NEGATIVE SYNDROME; OCCUPATIONAL THERAPY; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77953400957     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.58289     Document Type: Review

References (104)

1. Elkis H. Treatment-Resistant Schizophrenia. Psychiatr Clin N Am 2007;30:511-533
2. Itil T, Keskiner A, Fink M. Therapeutic studies in therapy resistant schizophrenic patients. Compr Psychiatry 1966;7:488-493
3. Kane J, Hognifeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
4. Miller A, McEvoy J, Jeste D, Marder SR. Treatment of chronic schizophrenia. In: Lieberman J, Stroup TS, Perkins D, editors. Textbook of schizophrenia. Washington, DC: The American Psychiatric Publishing; 2006. p. 365-381
5. Meltzer H, Kostacoglu A. Treatment-resistant schizophrenia. In: Lieberman J, Murray R, editors. Comprehensive care of schizophrenia: A textbook of clinical management. London (UK): Martin Dunitz; 2001. p. 181-203.
6. Csernansky JG, Yesavage JA, Maloney W, Kaplan J. The treatment response scale: A retrospective method of assessing response to neuroleptics. Am J Psychiatry 1983;140:1210-1213
7. May PR, Dencker SJ, Hubbard JW. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig (Germany): Viewag Verlag; 1988. p. 22-23
8. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-561
9. Brenner HD, Merlo MC. Definition of therapy-resistant schizophrenia and its assessment. Eur Psychiatry 1995;10:11s-7s.
10. Meltzer HY. Commentary: Defining treatment refractoriness in schizophrenia, Schizophr Bull 1990;16:563-565
11. Marder SR. Defining and characterizing treatment-resistant schizophrenia. Eur Psychiatry 1995;10:7s-10s.
12. Brenner HD, Merlo MC. Definition of therapy resistant schizophrenia and itsassessment. Eur Psychiatry1995;10:11s-7s.
13. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997;14:1-20.
14. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
15. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217.
16. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-508
17. Pickar D, Owen R, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-353
18. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
19. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
20. Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, et al. Impact of Clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999;156:88-93.
21. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-999
22. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526
23. Moncrieff J, Clozapine V. Conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination. Br J Psychiatry 2003;183:161-166
24. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomized trials. Schizophr Res 2002;56:1-10.
25. Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14:409-418
26. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
27. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
28. Solanki RK, Singh P, Swami MK. Clozapine current perspective. Indian J Psychiatry 2007;49:271-276
29. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
30. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31
31. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
32. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-723
33. Kupchik M, Spivak B, Mester R, Reznik I, Gonen N, Weizman A, et al. Combined electroconvulsive-clozapine therapy. Clin Neuopharmacol 2000;23:14-16
34. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003;42:607-618
35. Matthiasson P. Relationship between dopamine D2 receptor occupancy and clinical response in amisulpride augmentation of clozapine non response. J Psychopharmacol 2001;15:S41.
36. Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM, et al. Amisulpride augmentation of clozapine: An open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004;110:292-298
37. AgelinkMW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004;161:924-925
38. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia-case reports and review of literature. Pharmacopsychiatry 2004;37:26-31.
39. Ziegenbein M. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: An open clinical study. German J Psychiatry 2006;9:17-21.
40. Kampf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: A promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005;38:39-40.
41. Lim S, Pralea C, Schnitt J, Bowers MB Jr, Cooper C. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry 2004;65:1284-1285
42. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 2006;67:675-676
43. Ziegenbein M, Sieberer M, Calliess IT, Kropp S. Combination of clozapine and aripiprazole: A promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2005;39:840-841 (Pubitemid 43904480)
44. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-147
45. Rajarethinam R, Gilani S, Tancer M, DeQuardo J. Augmentation of clozapine partial responders with conventional antipsychotics. Schizophr Res 2003;60:97-98
46. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197
47. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113-115
48. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42:522-523
49. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003;64:215-216
50. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843-872
51. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olié JP, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultra-resistant schizophrenia. Clin Neuropharmacol 2006;29:28-33.
52. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-573
53. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-136
54. Anil Yadciodlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry 2005;66:63-72.
55. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482
56. Raskin S, Katz G, Zislin Z, Knobler HY, Durst R. Clozapine and risperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation. Acta Psychiatr Scand 2000;101:334-336
57. Akdede BB, Anil Yagcioglu AE, Alptekin K, Turgut TI, Tümü klü M, Yazici MK, et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: Effects on cognition. J Clin Psychiatry 2006;67:1912-1919
58. Peet M. Double blind placebo controlled trial of N-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Schizophr Res 1998;29:160-161
59. Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentanoic acid. Arch Gen Pschiatry 1998;55:188-189
60. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvärinen S, Eronen M, et al. Topiramate add-on in treatment-resistant schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005;66:1012-1015
61. Dursun M, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. J Psychopharmacol 2001;15: 297-301.
62. Millson RC, Owen JA, Lorberg GW, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry 2002;159:675.
63. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry1999;56:950.
64. Tiihonen J, Hallikainen T, Ryynänen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, et al. Lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial. Biol Psychiatry 2003;54:1241-1248
65. Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyürek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: A potent anticraving effect? J Psychopharmacol 2005;19:301-305
66. Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: Safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998;59:585-588
67. Dossenbach MR, Beuzen JN, Avnon M, Belmaker RH, Elizur A, Mark M, et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 2000;22:1021-1034
68. Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J Clin Psychiatry 2000;61:912-915
69. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study. J Clin Psychiatry 2002;63:931-935
70. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-411
71. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment resistant schizophrenia. Am J Psychiatry 1998;155:914-920
72. Martin J, Gomez JC, García-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: Results of an open label study: The Spanish group for the study of olanzapine in treatment-refractory schizophrenia. J Clin Psychiatry 1997;58:479-483
73. Dursun SM, Gardner DM, Bird DC, Flinn J. Olanzapine for patients with treatment refractory schizophrenia: A naturalistic case-series outcome study. Can J Psychiatry 1999;44:701-704
74. Sanders RD, Mossman D. An open trial of Olanzapine in patients with treatment refractory psychosis. J Clin Psychopharmacol 1999;19:62-66
75. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized double blind comparison of clozapine and high dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-285
76. Smith RC, Chua JW, Lipetsker B, Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: An open prospective study. J Clin Psychiatry 1996;57:460-466
77. Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment refractory schizophrenia. Am J Psychiatry1999;156:1374- 1379
78. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-bind study. Am J Psychiatry 1998;155:499-504.
79. Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, et al. An open comparison of clozapine and risperidone in treatment resistant schizophrenia. Pharmacopsychiatry 1998;31:25-29
80. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study. J Clin Psychiatry 1998;59:521-527
81. Szigethy E, Brent S, Findling RL. Quetiapine for refractory schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37:1127-1128
82. Reznik I, Benatov R, Sirota P. Seroquel in a resistant schizophrenic with negative and positive symptoms. Harefuah 1996;130:675-677
83. Kungel M, Ebrech M, Mondell S, Wagner P, Carson W, Marcus R. Efficacy and tolerability of aripiprazole compared to perphenazine in treatmentresistant schizophrenia. Pharmacopsychiatry 2003.
84. Crossman AM, Lindenmayer JP. Tolerability of high-dose aripiprazolein treatment-refractory schizophrenic patients. J Clin Psychiatry 2006;67: 1158-1159
85. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-731
86. Loebel AD, Khanna S, Rajadhyaksha S, Siu CO, Giller E, Potkin SG. Ziprasidone in treatment-resistant schizophrenia: A 52-week, Open-label Continuation study. 2007;68:1333-1338
87. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpride augmentation in people with schizophrenia partially responsive to clozapine: A double blind placebo-controlled study. Br J Psychiatry 1998;171:569-573
88. American Psychiatric Association, Practice Guidelines for the treatment of Schizophrenia. Washington, DC: American Psychiatric Association; 1997.
89. Okuma T, Yamashitu I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenia and schizoaffective disorders. Acta Psychiatr Scand 1989;80:250-259
90. Luchin DJ. Carbamazepine in violent nonepileptic schizophrenia. Psychopharmacol Bull 1984;20:571-596
91. Sussman N. Augmentation of antipsychotic drugs with selective serotonin reuptake inhibitors. Primary Psychiatry 1997;4:24-31.
92. Johns C, Thompson J. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995;21:607-619
93. Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006;59:230-234
94. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment refractory schizophrenia. Biol Psychiatry 2005;57;577-585
95. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment refractory schizophrenia. Clin Neuropharmacol 2002;25:272-275
96. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-457
97. Hellewell JS. Treatment-resistant schizophrenia: Reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60:14-19
98. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000;57:165-172
99. Pinto A, Pia SL, Mennella R, Giorgio D, DeSimone L. Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatr Serv 1999;50:901-904
100. Valmaggia LR, Van Der Gaag M, Tarrier N, Pijnenborg M, Slooff CJ. Cognitive behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication: Randomised controlled trial. Br J Psychiatry 2005;186:324-330
101. Rathod S, Kingdon D, Weiden P, Turkington D. Cognitive-behavioral therapy for medication-resistant schizophrenia: A review. J Psychiatr Pract 2008;14:22-33.
102. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, et al. Psychological treatments in schizophrenia: I, Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002;32:763-782
103. Randal P, Simpson AI, Laidlaw T. Can recovery-focused multimodal psychotherapy facilitate symptom and function improvement in people with treatment-resistant psychotic illness? A comparison study. Aust N Z J Psychiatry 2003;37:720-727
104. Buchain PC, Vizzotto AD, Henna Neto J, Elkis H. Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia. Rev Bras Psiquiatr 2003;25:26-30.